(Q37975242)

26 August 2017

Targeting the PI3K signaling pathway in cancer therapy (English)

1 reference

Ana Maria Gonzalez-Angulo

26 August 2017

series ordinal

2

object named as

Ana Maria Gonzalez-Angulo

1 reference

26 August 2017

Chandra Bartholomeusz

series ordinal

1

1 reference

PubMed ID

22239433

26 August 2017

language of work or name

English

0 references

publication date

12 January 2012

1 reference

Expert Opinion on Therapeutic Targets

26 August 2017

1 reference

26 August 2017

16

1 reference

26 August 2017

121-130

1 reference

26 August 2017

1

1 reference

Phosphoinositide 3-kinases: a conserved family of signal transducers

26 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II. Evidence for conserved alternative splicing in the 4-phosphatase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

The multiple roles of PTEN in tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Mouse modeling in oncologic preclinical and translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PTEN mutation spectrum in breast cancers and breast hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PIK3CA mutation associates with improved outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Current and future directions in mammalian target of rapamycin inhibitors development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Genetic pathways to primary and secondary glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PTEN signaling pathways in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PIK3CA mutations in glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PIK3CA mutations in in situ and invasive breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

The prevalence of PIK3CA mutations in gastric and colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PIK3CA mutations and copy number gains in human lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PIK3CA mutation and amplification in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

E17K substitution in AKT1 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Deregulated Akt3 activity promotes development of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

PTEN mutations are common in sporadic microsatellite stable colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.644788

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.28.727

Identifiers

DOI

10.1517/14728222.2011.644788

1 reference

26 August 2017

1 reference

PubMed ID

22239433